vs
Evolus, Inc.（EOLS）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Evolus, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.0倍（$73.1M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -14.6%，领先398.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 6.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 4.6%）
Evolus是一家聚焦医疗美容赛道的企业，主营非手术类美容治疗产品的研发与商业化，核心产品为可改善中度至重度皱眉纹的处方神经调节剂，服务覆盖北美、欧洲及亚太核心市场的医美机构与消费者。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
EOLS vs RIGL — 直观对比
营收规模更大
EOLS
是对方的1.0倍
$69.8M
营收增速更快
RIGL
高出14.5%
6.7%
净利率更高
RIGL
高出398.6%
-14.6%
两年增速更快
RIGL
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.1M | $69.8M |
| 净利润 | $-10.7M | $268.1M |
| 毛利率 | 66.9% | 91.5% |
| 营业利润率 | 23.8% | 33.2% |
| 净利率 | -14.6% | 384.0% |
| 营收同比 | 6.7% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.16 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EOLSRIGL
| Q1 26 | $73.1M | — | ||
| Q4 25 | $90.3M | $69.8M | ||
| Q3 25 | $69.0M | $69.5M | ||
| Q2 25 | $69.4M | $101.7M | ||
| Q1 25 | $68.5M | $53.3M | ||
| Q4 24 | $78.9M | $57.6M | ||
| Q3 24 | $61.1M | $55.3M | ||
| Q2 24 | $66.9M | $36.8M |
净利润EOLSRIGL
| Q1 26 | $-10.7M | — | ||
| Q4 25 | $130.0K | $268.1M | ||
| Q3 25 | $-15.7M | $27.9M | ||
| Q2 25 | $-17.1M | $59.6M | ||
| Q1 25 | $-18.9M | $11.4M | ||
| Q4 24 | $-6.8M | $14.3M | ||
| Q3 24 | $-19.2M | $12.4M | ||
| Q2 24 | $-11.3M | $-1.0M |
毛利率EOLSRIGL
| Q1 26 | 66.9% | — | ||
| Q4 25 | 65.7% | 91.5% | ||
| Q3 25 | 66.5% | 93.2% | ||
| Q2 25 | 65.3% | 95.6% | ||
| Q1 25 | 68.1% | 91.7% | ||
| Q4 24 | 66.7% | 89.9% | ||
| Q3 24 | 68.9% | 85.5% | ||
| Q2 24 | 70.3% | 92.4% |
营业利润率EOLSRIGL
| Q1 26 | 23.8% | — | ||
| Q4 25 | 4.7% | 33.2% | ||
| Q3 25 | -16.7% | 40.9% | ||
| Q2 25 | -14.7% | 60.1% | ||
| Q1 25 | -22.1% | 23.9% | ||
| Q4 24 | -2.9% | 28.9% | ||
| Q3 24 | -25.3% | 25.4% | ||
| Q2 24 | -11.5% | 1.2% |
净利率EOLSRIGL
| Q1 26 | -14.6% | — | ||
| Q4 25 | 0.1% | 384.0% | ||
| Q3 25 | -22.8% | 40.2% | ||
| Q2 25 | -24.7% | 58.6% | ||
| Q1 25 | -27.6% | 21.5% | ||
| Q4 24 | -8.6% | 24.9% | ||
| Q3 24 | -31.4% | 22.5% | ||
| Q2 24 | -17.0% | -2.8% |
每股收益（稀释后）EOLSRIGL
| Q1 26 | $-0.16 | — | ||
| Q4 25 | $0.01 | $14.11 | ||
| Q3 25 | $-0.24 | $1.46 | ||
| Q2 25 | $-0.27 | $3.28 | ||
| Q1 25 | $-0.30 | $0.63 | ||
| Q4 24 | $-0.11 | $0.82 | ||
| Q3 24 | $-0.30 | $0.70 | ||
| Q2 24 | $-0.18 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.8M | $155.0M |
| 总债务越低越好 | $156.4M | $52.5M |
| 股东权益账面价值 | — | $391.5M |
| 总资产 | $220.6M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EOLSRIGL
| Q1 26 | $49.8M | — | ||
| Q4 25 | $53.8M | $155.0M | ||
| Q3 25 | $43.5M | $137.1M | ||
| Q2 25 | $61.7M | $108.4M | ||
| Q1 25 | $67.9M | $77.1M | ||
| Q4 24 | $87.0M | $77.3M | ||
| Q3 24 | $85.0M | $61.1M | ||
| Q2 24 | $93.7M | $49.1M |
总债务EOLSRIGL
| Q1 26 | $156.4M | — | ||
| Q4 25 | $146.1M | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | $121.8M | $60.0M | ||
| Q4 24 | $121.5M | $60.0M | ||
| Q3 24 | $121.2M | $60.0M | ||
| Q2 24 | $120.9M | $60.0M |
股东权益EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | $-23.1M | $391.5M | ||
| Q3 25 | $-28.8M | $117.6M | ||
| Q2 25 | $-18.7M | $81.9M | ||
| Q1 25 | $-6.6M | $18.6M | ||
| Q4 24 | $5.5M | $3.3M | ||
| Q3 24 | $5.9M | $-14.6M | ||
| Q2 24 | $19.3M | $-29.9M |
总资产EOLSRIGL
| Q1 26 | $220.6M | — | ||
| Q4 25 | $225.9M | $513.6M | ||
| Q3 25 | $219.0M | $242.5M | ||
| Q2 25 | $228.8M | $206.7M | ||
| Q1 25 | $213.4M | $176.0M | ||
| Q4 24 | $232.6M | $164.0M | ||
| Q3 24 | $229.6M | $139.4M | ||
| Q2 24 | $233.8M | $128.4M |
负债/权益比EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 22.00× | 18.25× | ||
| Q3 24 | 20.58× | — | ||
| Q2 24 | 6.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | $22.0M | ||
| Q3 25 | $-14.7M | $24.0M | ||
| Q2 25 | $-24.8M | $30.5M | ||
| Q1 25 | $-15.6M | $-893.0K | ||
| Q4 24 | $4.8M | $14.5M | ||
| Q3 24 | $-5.7M | $21.7M | ||
| Q2 24 | $-6.5M | $302.0K |
自由现金流EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $-15.6M | — | ||
| Q2 25 | $-25.5M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $4.4M | — | ||
| Q3 24 | $-6.0M | — | ||
| Q2 24 | $-6.9M | — |
自由现金流率EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | — | ||
| Q3 25 | -22.7% | — | ||
| Q2 25 | -36.7% | — | ||
| Q1 25 | -23.3% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | -9.9% | — | ||
| Q2 24 | -10.4% | — |
资本支出强度EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — |
现金转化率EOLSRIGL
| Q1 26 | — | — | ||
| Q4 25 | 98.67× | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EOLS
| Product revenue, net | $72.7M | 99% |
| Service revenue | $390.0K | 1% |
RIGL
暂无分部数据
